Pfizer shares slump as support grows for COVID-19 vaccine patent waiverShares in COVID-19 vaccine manufacturers have taken a hit after the US signalled its support for waiving patents Share XPfizer shares slump as support grows for COVID-19 vaccine patent waiverhttps://pharmaphorum.com/news/pfizer-shares-slump-as-support-grows-for-covid-19-vaccine-patent-waiver/
Pfizer says COVID-19 jab could rake in $26bn this yearPfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it Share XPfizer says COVID-19 jab could rake in $26bn this yearhttps://pharmaphorum.com/news/pfizer-says-covid-19-jab-could-rake-in-26bn-this-year/
UK orders 60m ‘booster’ doses of Pfizer/BioNTech COVID vaccineThe UK has ordered an extra 60 million doses of the Pfizer/BioNTech COVID-19 vaccine, which could be used Share XUK orders 60m ‘booster’ doses of Pfizer/BioNTech COVID vaccinehttps://pharmaphorum.com/news/uk-orders-60m-booster-doses-of-pfizer-biontech-covid-vaccine/
UK Vaccine Taskforce head lifts lid on Novavax dealThe UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its Share XUK Vaccine Taskforce head lifts lid on Novavax dealhttps://pharmaphorum.com/news/novavax-developed-vaccine-in-uk-because-of-rd-opportunities/
EU orders another 100m doses of Pfizer/BioNTech COVID jabThe EU has continued a refocus of its COVID-19 vaccination drive on mRNA shots, ordering another 100 million Share XEU orders another 100m doses of Pfizer/BioNTech COVID jabhttps://pharmaphorum.com/news/eu-orders-another-100m-doses-of-pfizer-biontech-covid-jab/
Risk of brain clots higher with COVID than vaccine, study suggestsA study has suggested that the risk of getting a serious brain clot is eight to 10 times Share XRisk of brain clots higher with COVID than vaccine, study suggestshttps://pharmaphorum.com/news/risk-of-brain-clots-higher-with-covid-than-vaccine-study-suggests/
Pfizer/Myovant take relugolix contraceptive combination pill into phase 3Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of Share XPfizer/Myovant take relugolix contraceptive combination pill into phase 3https://pharmaphorum.com/news/pfizer-myovant-take-relugolix-contraceptive-combination-pill-into-phase-3/
AZ aims at Pfizer, GSK with potential new PARP cancer drugAstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in Share XAZ aims at Pfizer, GSK with potential new PARP cancer drughttps://pharmaphorum.com/news/az-aims-at-pfizer-gsk-with-potential-new-parp-cancer-drug/
South African variant may evade Pfizer/BioNTech vaccine, study findsThe coronavirus variant discovered in South Africa may evade Pfizer/BioNTech’s vaccine, according to a real-world data study conducted Share XSouth African variant may evade Pfizer/BioNTech vaccine, study findshttps://pharmaphorum.com/news/south-african-variant-may-evade-pfizer-biontech-vaccine-study-finds/
